Clinical trials: Graft -Versus-host-disease
Steroid-resistant Severe aGVHD
MSC for Severe aGVHD
Steroid-resistant acute graft-versus-host disease (aGVHD) is one of the most severe complications in the setting of allogeneic hematopoietic stem cell transplantation (HSCT), which cannot be significant benefit from the…
- Trial name
- NCT03631589
- Testing
- MSCs
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fujian Medical University
Graft Vs Host Disease
Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD
This is a single arm, open label, phase II clinical trial. Adult patients with hematological malignancies undergoing allogeneic HSCT from first- or second-degree haploidentical donor are eligible for the study if they meet the…
- Trial name
- NCT05621759
- Testing
- Cyclophosphamide, Abatacept, Tacrolimus
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- NYU Langone Health
Graft Versus Host Disease, Steroid Refractory GVHD
Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease
Acute Graft Versus Host Disease (GVHD) is a serious medical condition that is a common development after Bone Marrow Transplant (BMT).
- Conditions
- Graft Versus Host Disease, Steroid Refractory GVHD, Acute GVH Disease
- Trial name
- NCT01485055
- Testing
- Infliximab and Basiliximab
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Nationwide Children's Hospital
Myeloproliferative Disorders, Acute Myelogenous Leukemia
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
The are a variety of cancerous diseases of the blood and bone marrow that can be potentially cured by bone marrow transplantation (BMT).
- Conditions
- Myeloproliferative Disorders, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00003838
- Testing
- T-cell replete PBPC allograft, Methotrexate, Cyclosporine
- Where
- United States
- Volunteers
- 202 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Graft-versus-host-disease, Graft Vs Host Disease
Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
In this trial, the investigators will begin to explore the possibility that, as in mice, JAK1/2 inhibition with hematopoietic cell transplantation (HCT) may mitigate graft-versus-host-disease (GVHD) while retaining engraftment…
- Trial name
- NCT04131738
- Testing
- Baricitinib
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Washington University School of Medicine
Tourette's Disorder, Persistent (Chronic) Motor or Vocal Tic Disorder
Internet-delivered Behaviour Therapy for Children and Adolescents With Tourette's Disorder
The purpose of this trial is to evaluate the clinical efficacy, 12-month durability, and cost-effectiveness of BIP TIC - a therapist-guided and parent-guided internet-delivered behavioural intervention for children and…
- Trial name
- NCT03916055
- Testing
- Exposure and response prevention (ERP), Education on tics
- Where
- Sweden
- Volunteers
- 221 people
- Sponsor
- Karolinska Institutet
Hematopoietic Stem Cell Transplantation (HSCT), aGVHD
GMPA Versus PPI for Gastric Protection and aGVHD Risk
The goal of this clinical trial is to observe whether different gastric protection strategies affect the incidence of acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic stem cell…
- Conditions
- Hematopoietic Stem Cell Transplantation (HSCT), aGVHD, Infection, Mortality
- Trial name
- NCT07791849
- Testing
- Teprenone, Esomeprazole
- Where
- China
- Volunteers
- 198 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Haploidentical Hematopoietic Stem Cell Transplantation
Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation
The purpose of this study is to determine the response and toxicity rate of two different dosages (Individualized dosage VS. fixed dosage) of ATG as a prophylaxis for acute GVHD in haploidentical peripheral blood stem cell…
- Trial name
- NCT05166967
- Testing
- Individual Antithymocyte globulin, Antithymocyte globulin
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Chinese PLA General Hospital
Keratopathy, Sjogren's Syndrome
Blood Based Eyedrops From Different Sources in the Treatment of Severe Keratopathy
Topical preparations (eye drops) derived from the blood have become a relatively common treatment for more advanced forms of keratopathy.
- Conditions
- Keratopathy, Sjogren's Syndrome, GVHD - Graft-Versus-Host Disease
- Trial name
- NCT03064984
- Testing
- CBS eyedrops, PBS eyedrops
- Where
- 3 sites in Italy
- Volunteers
- 60 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Acute Graft-versus-Host Disease
Universal CNK-UT Therapy for Refractory aGVHD
This is a single arm, open-label, multi-center, pilot studies (Investigator Initiated Trial, IIT) to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of universal T-cells engineered with chimeric…
- Trial name
- CNK-UT (NCT06750133)
- Testing
- Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)
- Where
- 2 sites in China
- Volunteers
- 23 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00255684
- Testing
- graft-versus-tumor induction therapy, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Rochester
Myeloid Leukemia, Chronic
Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia
The first purpose of this study is to evaluate the persistence of the complete molecular remission in patients with Chronic Myeloid Leukemia after stopping imatinib treatment (determine by Reverse Transcription real-time…
- Trial name
- STIM (NCT00478985)
- Testing
- Imatinib ending
- Where
- 24 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Bordeaux
Chronic Ocular Graft-versus-host Disease
A Study of Stem Cells Lenses in the coGVHD Subjects
This study is a single dose, Phase I study to evaluate the safety, tolerability, and preliminary effectiveness of Stem cells Lenses in the coGVHD Subjects. Three subject's enrollments are Expected.
- Trial name
- NCT06952114
- Testing
- Stem Cells Lenses
- Volunteers
- 6 people
- Sponsor
- Guangdong ProCapZoom Biosciences Co., Ltd.
Chronic Graft Versus Host Disease, Steroid Refractory Graft Versus Host Disease
Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease
This phase I trial studies the side effects of leflunomide in treating patients with steroid dependent chronic graft versus host disease (cGVHD). cGVHD is a common complication of bone marrow transplant.
- Trial name
- NCT04212416
- Testing
- Leflunomide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Graft Vs Host Disease
Evaluation of the Impact of Reduced Immunosuppression
Graft-versus-host disease (GVHD) is a life-threatening complication of transplantation. It occurs when the donor graft contains immunologically competent T-cells that recognize the recipient as foreign.
- Trial name
- NCT05238155
- Testing
- antimetabolite
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Methodist Health System
Graft Versus Host Disease
Early Detection of Mucosal Abnormalities in Graft-versus-host Disease
Gastro-intestinal graft versus host disease (GVHD) is a major source of morbidity and mortality amongst allogenic hematopoietic stem cell transplantation (Allo-HSCT).
- Trial name
- E-mage (NCT02707354)
- Testing
- Probe based confocal laser endomicroscopy (Cellvizio)
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Nantes University Hospital
Graft Versus Host Disease, Systemic Scleroderma
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
This randomized phase II trial is evaluating how well imatinib mesylate works compared to rituximab in treating cutaneous sclerosis in patients with chronic graft- versus-host disease (GVHD).
- Trial name
- NCT01309997
- Testing
- imatinib mesylate, rituximab
- Where
- 10 sites in United States
- Volunteers
- 72 people
- Sponsor
- Lee, Stephanie
Severe Combined Immune Deficiency (SCID)
Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus
Background: Severe combined immune deficiency (SCID) is a group of conditions where the immune system does not work properly. The only cure for most SCIDs is a stem cell transplant (getting cells from a donor).
- Trial name
- NCT04370795
- Testing
- Sirolimus, Busulfan, Horse -Anti-thymocyte
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lymphoma, Leukemia
Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia
GVHD remains a major cause of morbidity and mortality following SCT. The current standard of care for prophylaxis against GVHD includes tacrolimus and methotrexate.
- Trial name
- NCT04961801
- Testing
- Acalabrutinib, tacrolimus, methotrexate
- Sponsor
- Shin Mineishi
Leukemia
A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors
This is a study designed to assess the safety of administration of up to 3 dose levels of eritoran in subjects undergoing or scheduled to undergo allogeneic bone marrow transplant (BMT).
- Trial name
- NCT00756912
- Testing
- E5564
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Eisai Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.